Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.860
+0.100 (2.66%)
At close: Mar 6, 2026, 4:00 PM EST
3.870
+0.010 (0.26%)
After-hours: Mar 6, 2026, 5:15 PM EST
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
59.73M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ImmuCell | 27.64M |
| TScan Therapeutics | 10.33M |
| NeurAxis | 3.36M |
| BeyondSpring | 1.88M |
| ImageneBio | 800.00K |
| Spruce Biosciences | 697.00K |
| Rallybio | 674.00K |
| Mereo BioPharma Group | 500.00K |
GRCE News
- 10 days ago - Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 23 days ago - Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 3 months ago - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - GlobeNewsWire
- 4 months ago - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - GlobeNewsWire
- 5 months ago - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - GlobeNewsWire
- 6 months ago - Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 - GlobeNewsWire